Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

(2017) Phillip G. Febbo et al.   Journal of the National Comprehensive Cancer Network

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma

(2013) Keith T. Flaherty   ANNALS OF INTERNAL MEDICINE

Cytomegalovirus Contributes to Glioblastoma in the Context of Tumor Suppressor Mutations

(2013) R. L. Price et al.   CANCER RESEARCH

The TERT MNS16A polymorphism contributes to cancer susceptibility: Meta-analysis of the current studies

(2013) Pin Chen et al.   GENE

Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA)

(2013) Patrick Hole et al.   JOURNAL OF NANOPARTICLE RESEARCH

Heparin blocks transfer of extracellular vesicles between donor and recipient cells

(2013) Nadia A. Atai et al.   JOURNAL OF NEURO-ONCOLOGY

NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival

(2013) Nishita M.S. Baldewpersad Tewarie et al.   MEDICAL HYPOTHESES

Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium

(2013) Pamela S. Jones et al.   Neurosurgical Focus

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(2013) F. Wang et al.   SCIENCE

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

The Complete Exosome Workflow Solution: From Isolation to Characterization of RNA Cargo

(2013) Jeoffrey Schageman et al.   Biomed Research International

BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles

(2013) Walter W Chen et al.   Molecular Therapy-Nucleic Acids

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

(2012) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

(2012) Xiao-Yang Liu et al.   ACTA NEUROPATHOLOGICA

Imaging Characteristics of Oligodendrogliomas That Predict Grade

(2012) L. Khalid et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors

(2012) Wen-Jing Xing et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas

(2012) Gordon Li et al.   JOURNAL OF NEURO-ONCOLOGY

Occult tumors presenting with negative imaging: analysis of the literature

(2012) Prashant Chittiboina et al.   JOURNAL OF NEUROSURGERY

Cytomegalovirus infection in early childhood may be protective against glioblastoma multiforme, while later infection is a risk factor

(2012) Steven Lehrer   MEDICAL HYPOTHESES

Oncogenic Viruses and Tumor Glucose Metabolism: Like Kids in a Candy Store

(2012) E. Noch et al.   MOLECULAR CANCER THERAPEUTICS

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Subgroup-specific structural variation across 1,000 medulloblastoma genomes

(2012) Paul A. Northcott et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

(2012) Huilin Shao et al.   NATURE MEDICINE

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

(2012) Shota Tanaka et al.   Nature Reviews Clinical Oncology

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Detection of IDH1 mutation in the plasma of patients with glioma

(2012) B. Boisselier et al.   NEUROLOGY

Pathology: Commonly Monitored Glioblastoma Markers: EFGR, EGFRvIII, PTEN, and MGMT

(2012) Joaquin Q. Camara-Quintana et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterizing Mutational Heterogeneity in a Glioblastoma Patient with Double Recurrence

(2012) Gabrielle C. Nickel et al.   PLoS One

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion

(2011) Walter Stummer et al.   ACTA NEUROCHIRURGICA

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study

(2011) C.P. Geer et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pathologic Characteristics of Pediatric Intracranial Pilocytic Astrocytomas and Their Impact on Outcome in 3 Countries

(2011) Tarik Tihan et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

Heterogeneity Maintenance in Glioblastoma: A Social Network

(2011) R. Bonavia et al.   CANCER RESEARCH

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

(2011) Carmen Balañá et al.   Clinical & Translational Oncology

Is Cytomegalovirus a Therapeutic Target in Glioblastoma?

(2011) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome

(2011) Angela Di Vinci et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1R132 Mutation Effects in Human Glioblastoma

(2011) Nadia A. Atai et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies

(2011) K. Masui et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

New similarity search based glioma grading

(2011) Katrin Haegler et al.   NEURORADIOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

(2011) Dora Dias-Santagata et al.   PLoS One

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences

(2011) Leonora Balaj et al.   Nature Communications

Glioma-derived mutations in IDH: From mechanism to potential therapy

(2010) Yuejun Fu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Biomarker-Driven Early Clinical Trials in Oncology

(2010) Daniel S. W. Tan et al.   CANCER JOURNAL

Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas

(2010) J. D. Schiffman et al.   CANCER RESEARCH

Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells

(2010) Wei Chen et al.   CANCER SCIENCE

MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential

(2010) Judith WM Jeuken et al.   JOURNAL OF PATHOLOGY

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Glioblastoma stem-like cells give rise to tumour endothelium

(2010) Rong Wang et al.   NATURE

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide

(2010) George C. Bobustuc et al.   NEURO-ONCOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma

(2009) Bryan D. Choi et al.   BRAIN PATHOLOGY

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

The importance of surgical resection in malignant glioma

(2009) Walter Stummer et al.   CURRENT OPINION IN NEUROLOGY

Genetic signature of adult gliomas and correlation with MRI features

(2009) Maria Grazia Bruzzone et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas

(2009) Tim Forshew et al.   JOURNAL OF PATHOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Sensitive digital quantification of DNA methylation in clinical samples

(2009) Meng Li et al.   NATURE BIOTECHNOLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

(2008) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

(2008) Johan Skog et al.   NATURE CELL BIOLOGY

High-grade glioma before and after treatment with radiation and Avastin: Initial observations

(2008) Ingeborg Fischer et al.   NEURO-ONCOLOGY

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

(2007) Duane A. Mitchell et al.   NEURO-ONCOLOGY